Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis. 2009

Vilma Urbonaviciute, and Silke Meister, and Barbara G Fürnrohr, and Benjamin Frey, and Eva Gückel, and Georg Schett, and Martin Herrmann, and Reinhard E Voll
IZKF, Research Group N2, Nikolaus Fiebiger Center of Molecular Medicine, University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.

The architectural chromosomal protein high-mobility group box 1 protein (HMGB1) acts as an alarmin when released from cells. It is involved in the pathogenesis of inflammatory and autoimmune diseases. HMGB1 can undergo post-translational modifications including oxidation. However, the mechanisms and functional relevance of HMGB1 oxidation are not yet understood. Increased concentrations of reactive oxygen species (ROS) have been reported during apoptosis and necrosis. Hence, we investigated the oxidative status of HMGB1 in dead cells. Immunoblot analyses under reducing and non-reducing conditions revealed that HMGB1 is oxidized in dead cells. Moreover, tagging of oxidized cysteine residues by a maleimide moiety linked to polyethylene glycol showed that HMGB1 passively released from primary and secondary necrotic cells was predominantly oxidized. Also HMGB1 in plasma of patients with systemic lupus was reversibly oxidized. In conclusion, HMGB1 undergoes reversible oxidative modifications at cysteine residues during cell death, which may modulate its biological properties.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D011499 Protein Processing, Post-Translational Any of various enzymatically catalyzed post-translational modifications of PEPTIDES or PROTEINS in the cell of origin. These modifications include carboxylation; HYDROXYLATION; ACETYLATION; PHOSPHORYLATION; METHYLATION; GLYCOSYLATION; ubiquitination; oxidation; proteolysis; and crosslinking and result in changes in molecular weight and electrophoretic motility. Amino Acid Modification, Post-Translational,Post-Translational Modification,Post-Translational Protein Modification,Posttranslational Modification,Protein Modification, Post-Translational,Amino Acid Modification, Posttranslational,Post-Translational Amino Acid Modification,Post-Translational Modifications,Post-Translational Protein Processing,Posttranslational Amino Acid Modification,Posttranslational Modifications,Posttranslational Protein Processing,Protein Processing, Post Translational,Protein Processing, Posttranslational,Amino Acid Modification, Post Translational,Modification, Post-Translational,Modification, Post-Translational Protein,Modification, Posttranslational,Modifications, Post-Translational,Modifications, Post-Translational Protein,Modifications, Posttranslational,Post Translational Amino Acid Modification,Post Translational Modification,Post Translational Modifications,Post Translational Protein Modification,Post Translational Protein Processing,Post-Translational Protein Modifications,Processing, Post-Translational Protein,Processing, Posttranslational Protein,Protein Modification, Post Translational,Protein Modifications, Post-Translational
D003545 Cysteine A thiol-containing non-essential amino acid that is oxidized to form CYSTINE. Cysteine Hydrochloride,Half-Cystine,L-Cysteine,Zinc Cysteinate,Half Cystine,L Cysteine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D019169 Jurkat Cells A CELL LINE derived from human T-CELL LEUKEMIA and used to determine the mechanism of differential susceptibility to anti-cancer drugs and radiation. Cell, Jurkat,Cells, Jurkat,Jurkat Cell
D024243 HMGB1 Protein A 24-kDa HMGB protein that binds to and distorts the minor grove of DNA. HMG1,Amphoterin,Box Protein 1, High Mobility Group,FM1 Gene Product,HMG 1 Protein,HMG-1 Protein,HMGB1,Heparin-Binding Protein p30,Heparin Binding Protein p30,p30, Heparin-Binding Protein

Related Publications

Vilma Urbonaviciute, and Silke Meister, and Barbara G Fürnrohr, and Benjamin Frey, and Eva Gückel, and Georg Schett, and Martin Herrmann, and Reinhard E Voll
January 2008, Arthritis research & therapy,
Vilma Urbonaviciute, and Silke Meister, and Barbara G Fürnrohr, and Benjamin Frey, and Eva Gückel, and Georg Schett, and Martin Herrmann, and Reinhard E Voll
February 2011, Rinsho byori. The Japanese journal of clinical pathology,
Vilma Urbonaviciute, and Silke Meister, and Barbara G Fürnrohr, and Benjamin Frey, and Eva Gückel, and Georg Schett, and Martin Herrmann, and Reinhard E Voll
December 2005, Critical care medicine,
Vilma Urbonaviciute, and Silke Meister, and Barbara G Fürnrohr, and Benjamin Frey, and Eva Gückel, and Georg Schett, and Martin Herrmann, and Reinhard E Voll
August 2018, Seminars in immunology,
Vilma Urbonaviciute, and Silke Meister, and Barbara G Fürnrohr, and Benjamin Frey, and Eva Gückel, and Georg Schett, and Martin Herrmann, and Reinhard E Voll
January 2016, Cell death discovery,
Vilma Urbonaviciute, and Silke Meister, and Barbara G Fürnrohr, and Benjamin Frey, and Eva Gückel, and Georg Schett, and Martin Herrmann, and Reinhard E Voll
June 2006, Cytokine & growth factor reviews,
Vilma Urbonaviciute, and Silke Meister, and Barbara G Fürnrohr, and Benjamin Frey, and Eva Gückel, and Georg Schett, and Martin Herrmann, and Reinhard E Voll
January 2018, Oncoimmunology,
Vilma Urbonaviciute, and Silke Meister, and Barbara G Fürnrohr, and Benjamin Frey, and Eva Gückel, and Georg Schett, and Martin Herrmann, and Reinhard E Voll
October 2015, Molecular medicine (Cambridge, Mass.),
Vilma Urbonaviciute, and Silke Meister, and Barbara G Fürnrohr, and Benjamin Frey, and Eva Gückel, and Georg Schett, and Martin Herrmann, and Reinhard E Voll
June 2013, Journal of autoimmunity,
Vilma Urbonaviciute, and Silke Meister, and Barbara G Fürnrohr, and Benjamin Frey, and Eva Gückel, and Georg Schett, and Martin Herrmann, and Reinhard E Voll
July 2023, Brain, behavior, and immunity,
Copied contents to your clipboard!